There are currently 32 active clinical trials seeking participants for Crohn's Disease research studies. The states with the highest number of trials for Crohn's Disease participants are Florida, Texas, California and New York.
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +188 locations
Conditions: Crohn's Disease, Obesity or Overweight
Register for Updates
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
NCT03167437
Recruiting
Background: Crohn s disease (CD) is an inflammatory bowel disease. It causes inflammation of the gut. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition. CD has no cure, but symptoms can sometimes be controlled with medicine. Researchers want to see if it is safe to treat CD with the medicine vorinostat. It is thought that vorinostat may reduce the inflammation process of CD. This may then help to relieve symptoms of CD. Participants who respond to Vorinostat w... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Crohn's Disease
Register for Updates
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, parti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/10/2025
Locations: Digestive Health Specialsits, Dothan, Alabama +52 locations
Conditions: Crohn's Disease
Register for Updates
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777
Recruiting
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/07/2025
Locations: University of California San Diego, La Jolla, California +82 locations
Conditions: Crohn's Disease
Register for Updates
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353
Recruiting
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is be... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/13/2025
Locations: Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona +82 locations
Conditions: Crohn's Disease
Register for Updates
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615
Recruiting
Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461) and TAK-279-UC-2001 (NCT06254950). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able... Read More
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
06/03/2025
Locations: Tyler Research Institute, LLC, Tyler, Texas
Conditions: Crohn's Disease, Ulcerative Colitis
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: Om Research, Lancaster, California +36 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910
Recruiting
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/28/2025
Locations: UCSD Medical Center, La Jolla, California +137 locations
Conditions: Crohn's Disease
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: GastroIntestinal BioSciences, Los Angeles, California +196 locations
Conditions: Crohn's Disease
Register for Updates
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289
Recruiting
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
03/12/2025
Locations: VVCRD Clinical Research, Garden Grove, California +56 locations
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555
Recruiting
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: GI Alliance - Sun City, Sun City, Arizona +19 locations
Conditions: Crohn's Disease
Register for Updates
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
NCT03256240
Recruiting
This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +14 locations
Conditions: Crohn's Disease
Register for Updates